First or Second Biologic in Inflammatory Bowel Disease: Combination Therapy or Monotherapy?
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams and Wilkins
Abstract
The therapeutic armamentarium for patients with inflammatory bowel disease has been expanding. Current guidelines make recommendations about whether patients who are biologic naive should be receiving biologic monotherapy or combination therapy, depending on the class of biologics. However, due to the limited available data, guidance to inform clinical practice for patients receiving their second or more biologic are lacking. We hereby review the available data about the use of biologic monotherapy or combination therapy with concomitant immunomodulator therapies in patients receiving their first as well as those receiving their second biologic. © 2021 Lippincott Williams and Wilkins. All rights reserved.
Description
Keywords
Biologic, Combination therapy, Ibd, Immunogenicity, Monotherapy, Biological products, Colitis, Combined modality therapy, Drug therapy, combination, Humans, Immunologic factors, Inflammatory bowel diseases, Biological product, Immunomodulating agent, Tumor necrosis factor inhibitor, Ustekinumab, Vedolizumab, Immunologic factor, Biological therapy, Clinical outcome, Comparative effectiveness, Human, Immunotherapy, Inflammatory bowel disease, Practice guideline, Review, Combination drug therapy, Multimodality cancer therapy